CN102670505B - 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 - Google Patents
制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 Download PDFInfo
- Publication number
- CN102670505B CN102670505B CN201110239124.1A CN201110239124A CN102670505B CN 102670505 B CN102670505 B CN 102670505B CN 201110239124 A CN201110239124 A CN 201110239124A CN 102670505 B CN102670505 B CN 102670505B
- Authority
- CN
- China
- Prior art keywords
- hfa
- preparation
- mixed liquor
- medicine
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007921 spray Substances 0.000 title abstract description 28
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 208000023504 respiratory system disease Diseases 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 28
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 28
- 239000003380 propellant Substances 0.000 claims abstract description 15
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims abstract description 13
- 239000003246 corticosteroid Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 31
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 18
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 14
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 13
- 229960002714 fluticasone Drugs 0.000 claims description 13
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 11
- 229960004436 budesonide Drugs 0.000 claims description 11
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 10
- 229960002052 salbutamol Drugs 0.000 claims description 10
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 claims description 7
- 229960002789 procaterol hydrochloride Drugs 0.000 claims description 7
- 239000003513 alkali Chemical group 0.000 claims description 6
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 5
- 229960002848 formoterol Drugs 0.000 claims description 5
- 239000000052 vinegar Substances 0.000 claims description 5
- 235000021419 vinegar Nutrition 0.000 claims description 5
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 4
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 4
- 229960000193 formoterol fumarate Drugs 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical group C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229960003728 ciclesonide Drugs 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229960002288 procaterol Drugs 0.000 claims description 3
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 229960000289 fluticasone propionate Drugs 0.000 claims description 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 27
- 239000000725 suspension Substances 0.000 abstract description 7
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000000375 suspending agent Substances 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 description 34
- 238000009472 formulation Methods 0.000 description 31
- 238000000034 method Methods 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- 238000009826 distribution Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000005507 spraying Methods 0.000 description 9
- 230000001133 acceleration Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000013112 stability test Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000006184 cosolvent Substances 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- OBRNDARFFFHCGE-QDSVTUBZSA-N arformoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-QDSVTUBZSA-N 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061876 Obstruction Diseases 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 229940092705 beclomethasone Drugs 0.000 description 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 alcohol compound Chemical class 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- AEQDBKHAAWUCMT-CVHDTDHSSA-N hydron;8-hydroxy-5-[(1r,2s)-1-hydroxy-2-(propan-2-ylamino)butyl]-1h-quinolin-2-one;chloride Chemical compound Cl.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC AEQDBKHAAWUCMT-CVHDTDHSSA-N 0.000 description 3
- 229940071648 metered dose inhaler Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229960004017 salmeterol Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 208000030303 breathing problems Diseases 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 150000001884 corticosterones Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MMVPLEUBMWUYIB-UHFFFAOYSA-M 2-acetyloxypropyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CC(C)OC(C)=O MMVPLEUBMWUYIB-UHFFFAOYSA-M 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920000538 Poly[(phenyl isocyanate)-co-formaldehyde] Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940124816 budesonide HFA MDI Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- 229950001669 tipredane Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW100109223A TWI399202B (zh) | 2011-03-17 | 2011-03-17 | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
| CN201110239124.1A CN102670505B (zh) | 2011-03-17 | 2011-08-19 | 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 |
| PH1/2014/500440A PH12014500440A1 (en) | 2011-08-19 | 2012-02-14 | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| EP12825882.9A EP2749275A4 (en) | 2011-03-17 | 2012-02-14 | METHOD FOR PREPARING A DOSING INHALER-SPRAYER FOR THE TREATMENT OF RESPIRATORY DISEASE |
| US14/239,722 US9241904B1 (en) | 2011-08-19 | 2012-02-14 | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| PCT/CN2012/071129 WO2013026269A1 (zh) | 2011-03-17 | 2012-02-14 | 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 |
| SG2014011597A SG2014011597A (en) | 2011-03-17 | 2012-02-14 | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| KR1020147004283A KR101586273B1 (ko) | 2011-03-17 | 2012-02-14 | 호흡기 질환 치료용 정량분무식 흡입제의 제조 방법 |
| AU2012300082A AU2012300082B2 (en) | 2011-03-17 | 2012-02-14 | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| CA2845258A CA2845258C (en) | 2011-03-17 | 2012-02-14 | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| JP2014526363A JP5938476B2 (ja) | 2011-03-17 | 2012-02-14 | 呼吸器疾患を治療するための定量噴霧式吸入剤を調製する方法 |
| MYPI2014700325A MY171271A (en) | 2011-08-19 | 2012-02-14 | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| RU2014104996/15A RU2582218C2 (ru) | 2011-03-17 | 2012-02-14 | Способ получения дозирующего распыляющего ингалятора для лечения респираторного заболевания |
| NZ621362A NZ621362B2 (en) | 2011-08-19 | 2012-02-14 | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| BR112014003907-0A BR112014003907A2 (pt) | 2011-08-19 | 2012-02-14 | método para preparar inalador pulverizado de dose medida para tratar doença respiratória |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW100109223 | 2011-03-17 | ||
| TW100109223A TWI399202B (zh) | 2011-03-17 | 2011-03-17 | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
| CN201110239124.1A CN102670505B (zh) | 2011-03-17 | 2011-08-19 | 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102670505A CN102670505A (zh) | 2012-09-19 |
| CN102670505B true CN102670505B (zh) | 2017-05-24 |
Family
ID=54253387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110239124.1A Active CN102670505B (zh) | 2011-03-17 | 2011-08-19 | 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2749275A4 (https=) |
| JP (1) | JP5938476B2 (https=) |
| KR (1) | KR101586273B1 (https=) |
| CN (1) | CN102670505B (https=) |
| AU (1) | AU2012300082B2 (https=) |
| CA (1) | CA2845258C (https=) |
| RU (1) | RU2582218C2 (https=) |
| SG (1) | SG2014011597A (https=) |
| TW (1) | TWI399202B (https=) |
| WO (1) | WO2013026269A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6739343B2 (ja) * | 2014-09-30 | 2020-08-12 | 株式会社エンビジョンＡｅｓｃエナジーデバイス | リチウムイオン二次電池の製造方法 |
| CN109464429B (zh) * | 2018-12-13 | 2021-04-27 | 上海方予健康医药科技有限公司 | 一种吸入压力定量气雾剂药物组合物及其制备方法 |
| CN110025578B (zh) * | 2019-04-10 | 2021-06-15 | 深圳市新阳唯康科技有限公司 | 一种治疗哮喘类肺部疾病的共无定形粉末及其制备方法 |
| WO2021195328A1 (en) * | 2020-03-25 | 2021-09-30 | Insmed Incorporated | Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof |
| FR3137830A1 (fr) * | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004075896A1 (en) * | 2003-02-27 | 2004-09-10 | Chiesi Farmaceutici S.P.A. | Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients |
| CN1625392A (zh) * | 2002-02-01 | 2005-06-08 | 阿斯利康(瑞典)有限公司 | 用于吸入的组合物 |
| CN1711093A (zh) * | 2002-11-15 | 2005-12-21 | 阿斯利康(瑞典)有限公司 | 最小化由于粘附于设备表面而损失的方法 |
| CN101384248A (zh) * | 2006-02-09 | 2009-03-11 | 贝林格尔英格海姆法玛两合公司 | 用于具有二种或多种活性剂以及至少一种表面活性剂的气雾剂的药物制剂 |
| CN102416179A (zh) * | 2010-09-28 | 2012-04-18 | 健乔信元医药生技股份有限公司 | 用于哮喘的吸入性复方组合物 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5776434A (en) | 1988-12-06 | 1998-07-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5439670A (en) | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| MX9203481A (es) | 1990-10-18 | 1992-07-01 | Minnesota Mining & Mfg | Formulaciones. |
| ZA924164B (en) | 1991-06-10 | 1993-02-24 | Schering Corp | Non-chlorofluorocarbon aerosol formulations |
| US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
| US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| US5916540A (en) | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
| DK0616524T3 (da) | 1991-12-12 | 1999-06-21 | Glaxo Group Ltd | Lægemidler |
| US5744123A (en) | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| US5736124A (en) | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| ES2079210T3 (es) | 1991-12-12 | 1996-01-01 | Glaxo Group Ltd | Formulacion farmaceutica de aerosol. |
| US5683676A (en) | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
| EP0617610B1 (en) | 1991-12-18 | 1997-03-19 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5833950A (en) | 1992-07-31 | 1998-11-10 | Glaxo Group Limited | Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate |
| ES2119219T5 (es) | 1993-07-15 | 2011-05-11 | Minnesota Mining And Manufacturing Company | Cierres estancos para uso en un dispositivo para suministrar un aerosol. |
| EP0806940B1 (en) | 1994-12-22 | 2003-04-09 | AstraZeneca AB | Aerosol drug formulations |
| US6013245A (en) | 1995-01-26 | 2000-01-11 | Glaxo Group Limited | Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant |
| GB9626960D0 (en) | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
| AU718967B2 (en) * | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
| US5891420A (en) | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation |
| US5891419A (en) | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe flunisolide aerosol formulations for oral inhalation |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| JP3610426B2 (ja) | 1998-06-04 | 2005-01-12 | 東京エレクトロン株式会社 | 基板姿勢制御装置 |
| JP4570251B2 (ja) * | 1998-07-24 | 2010-10-27 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
| US6458338B1 (en) | 1998-09-22 | 2002-10-01 | Aeropharm Technology Incorporated | Amino acid stabilized medicinal aerosol formulations |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| AU7026800A (en) | 1999-09-11 | 2001-04-17 | Glaxo Group Limited | Pharmaceutical formulation of fluticasone propionate |
| ES2238334T3 (es) * | 1999-12-24 | 2005-09-01 | Glaxo Group Limited | Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona. |
| US6540983B1 (en) | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
| US6540982B1 (en) | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
| US6464959B1 (en) | 2000-05-01 | 2002-10-15 | Aeropharm Technology Incorporated | Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer |
| US6548049B1 (en) | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US6447750B1 (en) | 2000-05-01 | 2002-09-10 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US6532684B1 (en) * | 2000-10-12 | 2003-03-18 | General Electric Company | System for cleaning pressurized containers |
| EP3384931B1 (en) | 2002-03-01 | 2019-07-24 | Chiesi Farmaceutici S.p.A. | Formoterol superfine formulation |
| GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| CN103462894A (zh) * | 2005-03-16 | 2013-12-25 | 霍尼韦尔国际公司 | 药物递送制剂、装置和方法 |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| TWI495466B (zh) * | 2010-09-23 | 2015-08-11 | Intech Biopharm Ltd | 用於氣喘之吸入性複方組合物 |
-
2011
- 2011-03-17 TW TW100109223A patent/TWI399202B/zh active
- 2011-08-19 CN CN201110239124.1A patent/CN102670505B/zh active Active
-
2012
- 2012-02-14 RU RU2014104996/15A patent/RU2582218C2/ru not_active IP Right Cessation
- 2012-02-14 WO PCT/CN2012/071129 patent/WO2013026269A1/zh not_active Ceased
- 2012-02-14 JP JP2014526363A patent/JP5938476B2/ja not_active Expired - Fee Related
- 2012-02-14 EP EP12825882.9A patent/EP2749275A4/en not_active Withdrawn
- 2012-02-14 CA CA2845258A patent/CA2845258C/en not_active Expired - Fee Related
- 2012-02-14 KR KR1020147004283A patent/KR101586273B1/ko not_active Expired - Fee Related
- 2012-02-14 SG SG2014011597A patent/SG2014011597A/en unknown
- 2012-02-14 AU AU2012300082A patent/AU2012300082B2/en not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1625392A (zh) * | 2002-02-01 | 2005-06-08 | 阿斯利康(瑞典)有限公司 | 用于吸入的组合物 |
| CN1711093A (zh) * | 2002-11-15 | 2005-12-21 | 阿斯利康(瑞典)有限公司 | 最小化由于粘附于设备表面而损失的方法 |
| EP1633369B1 (en) * | 2002-11-15 | 2007-04-18 | AstraZeneca AB | Process to minimize loss through adhesion to equipment surfaces |
| WO2004075896A1 (en) * | 2003-02-27 | 2004-09-10 | Chiesi Farmaceutici S.P.A. | Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients |
| CN101384248A (zh) * | 2006-02-09 | 2009-03-11 | 贝林格尔英格海姆法玛两合公司 | 用于具有二种或多种活性剂以及至少一种表面活性剂的气雾剂的药物制剂 |
| CN102416179A (zh) * | 2010-09-28 | 2012-04-18 | 健乔信元医药生技股份有限公司 | 用于哮喘的吸入性复方组合物 |
Non-Patent Citations (1)
| Title |
|---|
| Development of a pMDI formulation containing budesonide;E Robins等;《Indian Journal of Pharmceutical Sciences》;20071231;第69卷(第5期);第722-724页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012300082A1 (en) | 2014-03-06 |
| JP2014527056A (ja) | 2014-10-09 |
| WO2013026269A1 (zh) | 2013-02-28 |
| CA2845258C (en) | 2016-05-10 |
| SG2014011597A (en) | 2014-03-28 |
| KR20140042898A (ko) | 2014-04-07 |
| KR101586273B1 (ko) | 2016-01-18 |
| TW201238591A (en) | 2012-10-01 |
| EP2749275A4 (en) | 2015-08-19 |
| RU2014104996A (ru) | 2015-09-27 |
| EP2749275A1 (en) | 2014-07-02 |
| TWI399202B (zh) | 2013-06-21 |
| RU2582218C2 (ru) | 2016-04-20 |
| CA2845258A1 (en) | 2013-02-28 |
| NZ621362A (en) | 2015-08-28 |
| AU2012300082B2 (en) | 2016-05-19 |
| JP5938476B2 (ja) | 2016-06-22 |
| CN102670505A (zh) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1324749B1 (en) | Medicinal aerosol formulations | |
| CN106074359A (zh) | 用于加压计量吸入器的药物溶液制剂 | |
| US20090246149A1 (en) | Medicinal aerosol formulations | |
| AU2002211311A1 (en) | Medicinal aerosol formulations | |
| CN102670505B (zh) | 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 | |
| JP3264496B2 (ja) | クロロフルオロカーボンを含まないモメタゾンフロエートエーロゾルの処方物 | |
| Smyth | Propellant-driven metered-dose inhalers for pulmonary drug delivery | |
| US7163672B2 (en) | Pharmaceutical aerosol formulation | |
| JP2005514437A (ja) | イオン対複合体を含む医薬用エアロゾル製剤 | |
| CN106581010A (zh) | 一种气溶胶制剂及定量吸入气雾剂 | |
| US9241904B1 (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease | |
| US12383516B1 (en) | Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent | |
| HK1176550A (en) | The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases | |
| HK1176550B (en) | The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases | |
| More et al. | Formulation and Development of a" Pressurised Metered Dose Inhalation" beclomethasone 250 mcg | |
| WO2020152548A1 (en) | Stable aerosol inhalation compositions of formoterol | |
| Ridder | Nanoparticle formulations in HFA propellants | |
| MX2007009836A (es) | Formulaciones en aerosol conteniendo una mezcla de propelentes. | |
| HK1018206B (en) | Chlorofluorocarbon-free mometasone furoate aerosol formulations | |
| MXPA99001786A (en) | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1176550 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1176550 Country of ref document: HK |